Sunovion Pharmaceuticals Inc. Announces Dose Ranging Data from Phase 2 Study of SUN-101 (Glycopyrrolate) Inhalation Solution for Treatment of Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)